Hua Medicine (HKSE:02552) Long-Term Debt : HK$116.86 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Hua Medicine Long-Term Debt?

Hua Medicine's Long-Term Debt for the quarter that ended in Dec. 2023 was HK$116.86 Mil.

Hua Medicine's quarterly Long-Term Debt increased from Dec. 2022 (HK$0.00 Mil) to Jun. 2023 (HK$63.09 Mil) and increased from Jun. 2023 (HK$63.09 Mil) to Dec. 2023 (HK$116.86 Mil).

Hua Medicine's annual Long-Term Debt stayed the same from Dec. 2021 (HK$0.00 Mil) to Dec. 2022 (HK$0.00 Mil) but then increased from Dec. 2022 (HK$0.00 Mil) to Dec. 2023 (HK$116.86 Mil).

Hua Medicine Long-Term Debt Historical Data

The historical data trend for Hua Medicine's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hua Medicine Long-Term Debt Chart

Hua Medicine Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

116.86

Hua Medicine Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Debt	Get a 7-Day Free Trial										-	-	-	63.09	116.86

Hua Medicine (HKSE:02552) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Hua Medicine Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Hua Medicine's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Hua Medicine (HKSE:02552) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hua Medicine (HKSE:02552) » Definitions » Long-Term Debt

Traded in Other Exchanges

N/A

Address

Lane 36, Xuelin Road, Hua Medicine, Building 2, Pudong New Area, Shanghai, CHN, 201203

Website

https://www.huamedicine.com

Hua Medicine is an investment holding company. It is engaged in development and commercialization of a global first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. The group majorly operates in the PRC. Some of its products are Dorzagliatin + Metformin, Dorzagliatin, Dorzagliatin + Pioglitazone and mGLUR5 NAM, among others.

Hua Medicine (HKSE:02552) Headlines

No Headlines